361 related articles for article (PubMed ID: 27380916)
1. The current status of checkpoint inhibitors in metastatic bladder cancer.
Fahmy O; Khairul-Asri MG; Stenzl A; Gakis G
Clin Exp Metastasis; 2016 Oct; 33(7):629-35. PubMed ID: 27380916
[TBL] [Abstract][Full Text] [Related]
2. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
3. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
Katz H; Wassie E; Alsharedi M
Med Oncol; 2017 Sep; 34(10):170. PubMed ID: 28864844
[TBL] [Abstract][Full Text] [Related]
4. Atezolizumab in urothelial bladder carcinoma.
Hamilou Z; Lavaud P; Loriot Y
Future Oncol; 2018 Feb; 14(4):331-341. PubMed ID: 29135284
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
6. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment.
Chen YM
J Chin Med Assoc; 2017 Jan; 80(1):7-14. PubMed ID: 27693088
[TBL] [Abstract][Full Text] [Related]
8. Emerging role of checkpoint inhibition in localized bladder cancer.
Singh P; Black P
Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
[TBL] [Abstract][Full Text] [Related]
9. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
[TBL] [Abstract][Full Text] [Related]
10. From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma.
Hussain SA; Birtle A; Crabb S; Huddart R; Small D; Summerhayes M; Jones R; Protheroe A
Eur Urol Oncol; 2018 Dec; 1(6):486-500. PubMed ID: 31158093
[TBL] [Abstract][Full Text] [Related]
11. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.
Bellmunt J; Powles T; Vogelzang NJ
Cancer Treat Rev; 2017 Mar; 54():58-67. PubMed ID: 28214651
[TBL] [Abstract][Full Text] [Related]
12. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
Sgambato A; Casaluce F; Gridelli C
Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
[TBL] [Abstract][Full Text] [Related]
13. Role of Checkpoint Inhibition in Localized Bladder Cancer.
Hahn NM; Necchi A; Loriot Y; Powles T; Plimack ER; Sonpavde G; Roupret M; Kamat AM
Eur Urol Oncol; 2018 Aug; 1(3):190-198. PubMed ID: 31102620
[TBL] [Abstract][Full Text] [Related]
14. Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.
Faiena I; Cummings AL; Crosetti AM; Pantuck AJ; Chamie K; Drakaki A
Drug Des Devel Ther; 2018; 12():209-215. PubMed ID: 29416316
[TBL] [Abstract][Full Text] [Related]
15. [Not Available].
Thibault C
Bull Cancer; 2018 Dec; 105 Suppl 1():S43-S49. PubMed ID: 30595198
[TBL] [Abstract][Full Text] [Related]
16. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors for metastatic bladder cancer.
Massari F; Di Nunno V; Cubelli M; Santoni M; Fiorentino M; Montironi R; Cheng L; Lopez-Beltran A; Battelli N; Ardizzoni A
Cancer Treat Rev; 2018 Mar; 64():11-20. PubMed ID: 29407369
[TBL] [Abstract][Full Text] [Related]
19. Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
Bednova O; Leyton JV
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019653
[TBL] [Abstract][Full Text] [Related]
20. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
